Ho Wah Genting Bhd announced that the United States Food and Drug Administration (FDA) has responded to the second communication to its joint ventured US-based E-Mo Biology Inc. (EBI).
EBI was requested to provide further information on the Investigational New Drug (IND) application which proposes the use of existing poliomyelitis virus vaccines (polio vaccines) for the prevention of Covid-19.
The company had, on Aug 14, via its subsidiary HWGB Biotech Sdn Bhd (HWGB Biotech) signed a joint venture agreement with EBI for the research and development of vaccines, immunological treatment and diagnostic product development in relation to the Covid-19 virus.
EBI was approved by the FDA to conduct phase IV clinical trials for a proposed Covid-19 vaccine based on the polio vaccines.
“The FDA approval to conduct the clinical trials is really a step closer for us to our goal of producing a Covid-19 vaccine. Upon completion of the clinic trials, HWGB Biotech enjoy exclusive rights to start the production and distribution of the vaccines to assist in limiting the pandemic’s impact,” its CEO Datuk Aaron Lim said.
Under the JV, EBI is also responsible for R&D, testing, registration and commercialisation of five provisional patent applications and other applications related to the patents, which EBI owns.
On June 30, HWGB diversified its existing businesses to include healthcare-related industry which mainly involved in health supplements, biotechnology and health technology.